Endovascular Engineering (E2)

Stub active Updated Apr 7, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Menlo Park, California
Latest Stage Series C
Total Raised $80M
Sector
medical-devices healthtech

Investors

norwest-venture-partners series-c (2026)

Founders

Dan Rose CEO

About

Endovascular Engineering (E2) is a Menlo Park-based commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE) 1. The company developed the Helo Thrombectomy Platform for the treatment of pulmonary embolism, featuring a patented dual-action mechanism that integrates aspiration with mechanical clot disruption 1.

Funding History

Date Round Amount Lead Co-investors
2026-04-07 Series C $80M (oversubscribed) Gilde Healthcare, Norwest Sante Ventures, 415 Capital, S3 Ventures, Panakes Partners, M&L Healthcare Investments 1

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources

  1. BioSpace, “E2 (Endovascular Engineering) Raises $80 Million Series C to Advance Next-Generation Thrombectomy Platform,” April 7, 2026. https://www.biospace.com/press-releases/e2-endovascular-engineering-raises-80-million-series-c-to-advance-next-generation-thrombectomy-platform-as-pulmonary-embolism-treatment-evolves↩↩↩